Cite
HARVARD Citation
Appleby, N. et al. (2018). Risk adjusted therapy in chronic lymphocytic leukemia: a phase II cancer trials Ireland (CTRIAL-IE [ICORG 07-01]) study of fludarabine, cyclophosphamide, and rituximab therapy evaluating response adapted, abbreviated frontline therapy with FCR in non-del(17p) CLL. Leukemia & lymphoma. 59 (6), pp. 1338-1347. [Online].